Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1997-2-18
|
pubmed:abstractText |
The relevance of quantitative determinations of urinary deoxypyridinolines (DPY) and pyridinolines (PY), and of serum type I collagen carboxyterminal cross-linked telopeptides (ICTP), has been evaluated for patient monitoring in multiple myeloma (MM). In 178 untreated MM patients, a clear correlation was found between ICTP concentrations, bone destructions and serum calcium levels. Furthermore, serum ICTP, urinary DPY and PY concentrations were estimated before and during treatment in a further 33 MM patients randomly allocated to four groups receiving intravenous melphalan/prednisone (MivP) chemotherapy alone, or MivP in combination with three different doses of i.v. clodronate. 1800 mg of i.v. clodronate combined monthly with MivP induced a rapid and sustained reduction in bone resorption parameters to the normal range, a result not obtained with either MivP alone, or with a lower clodronate dose. While confirming the relevance of determining pyridinium cross-links for estimating bone resorption in MM, our data indicate that measurements of these parameters could be useful for dose finding and monitoring of bisphosphonate therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amino Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Clodronic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/collagen type I trimeric...,
http://linkedlifedata.com/resource/pubmed/chemical/deoxypyridinoline,
http://linkedlifedata.com/resource/pubmed/chemical/pyridinoline
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32A
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2053-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9014744-Adult,
pubmed-meshheading:9014744-Aged,
pubmed-meshheading:9014744-Aged, 80 and over,
pubmed-meshheading:9014744-Amino Acids,
pubmed-meshheading:9014744-Bone Resorption,
pubmed-meshheading:9014744-Clodronic Acid,
pubmed-meshheading:9014744-Collagen,
pubmed-meshheading:9014744-Collagen Type I,
pubmed-meshheading:9014744-Humans,
pubmed-meshheading:9014744-Middle Aged,
pubmed-meshheading:9014744-Multiple Myeloma,
pubmed-meshheading:9014744-Neoplasm Staging,
pubmed-meshheading:9014744-Paraneoplastic Syndromes,
pubmed-meshheading:9014744-Peptides,
pubmed-meshheading:9014744-Pilot Projects,
pubmed-meshheading:9014744-Tumor Markers, Biological
|
pubmed:year |
1996
|
pubmed:articleTitle |
Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy--a pilot study of the German Myeloma Treatment Group (GMTG).
|
pubmed:affiliation |
Abt. Klinische Immunologie, Medizinische Hochschule Hannover, Germany.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|